Xu 2007.

Methods	Allocation: randomised. Blindness: not stated. Duration: 8 weeks.
Participants	Diagnosis: schizophrenia (CCMD‐3). N = 160. Age: 16‐50. Sex: 88 men 72 women. History: not stated. Inclusion criteria: Blood, urine and biochemical tests normal. Exclusion criteria: Brain organic mental disorders; drug induced mental disorders.
Interventions	1. WDD (please see details in Table 5) + clozapine: dose clozapine 50 mg/d to 100 mg/d. N = 80. 2. Clozapine: dose clozapine 200‐400mg/d. N = 80.
Outcomes	Global state: cure (binary BPRS scores ‐ reduced >75%, 50% to 75%, 25% to 50%, no effect ‐ < 25%). Adverse events: insomnia, sleepiness, nausea or vomiting, constipation, dizzying or headache, EPS, EEG abnormal, liver function abnormal (TESS).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly divided in to intervention group and control …"
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data.
Selective reporting (reporting bias)	Low risk	We were unable to locate original study protocol, however, all outcomes listed in the 'methods' section of the paper appear to have been measured and reported.
Other bias	Low risk	No obvious other bias.